Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (321-330 of 584) with videos related to

Pageof 59
Sort By:
Advances in Therapy|February 28, 2026
Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid LeukemiaJustin M Watts, Eunice S Wang, Brian A Jonas, et al.
Leukemia|January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cellsJ A Burger, N S Velev, E J Jabbour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, et al.
The Lancet. Haematology|December 22, 2015
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Sara S Strom, Susan O'Brien, et al.
Blood Cancer Journal|July 15, 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaZ Gong, L J Medeiros, J E Cortes, et al.
International Journal of Hematology|April 14, 2021
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trialCharles Chuah, Liang Piu Koh, Tontanai Numbenjapon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2012
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJorge E Cortes, Dong-Wook Kim, Hagop M Kantarjian, et al.
Future Oncology (London, England)|September 14, 2019
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trialsJorge E Cortes, Hervé Dombret, Akil Merchant, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Journal of Hematology & Oncology|December 19, 2024
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE studyTimothy P Hughes, Giuseppe Saglio, Jan Geissler, et al.
Pageof 59

Showing results (321-330 of 584) with videos related to

Sort By:
Pageof 59
Advances in Therapy|February 28, 2026
Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid LeukemiaJustin M Watts, Eunice S Wang, Brian A Jonas, et al.
Leukemia|January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cellsJ A Burger, N S Velev, E J Jabbour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, et al.
The Lancet. Haematology|December 22, 2015
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Sara S Strom, Susan O'Brien, et al.
Blood Cancer Journal|July 15, 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaZ Gong, L J Medeiros, J E Cortes, et al.
International Journal of Hematology|April 14, 2021
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trialCharles Chuah, Liang Piu Koh, Tontanai Numbenjapon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2012
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJorge E Cortes, Dong-Wook Kim, Hagop M Kantarjian, et al.
Future Oncology (London, England)|September 14, 2019
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trialsJorge E Cortes, Hervé Dombret, Akil Merchant, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Journal of Hematology & Oncology|December 19, 2024
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE studyTimothy P Hughes, Giuseppe Saglio, Jan Geissler, et al.
Pageof 59